Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Metabolic Syndrome, Hypertension
Interventions: Placebo, Enalapril 5mg, Enalapril 10mg, Sitagliptin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Interventions: Iloprost, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 9
States / cities: Torrance, California • Jacksonville, Florida • Chicago, Illinois + 6 more

Conditions: Metabolic Syndrome, Hypertension
Interventions: 14 Nitrogen (N) Sodium Nitrite, Placebo; Drug
Lead sponsor: Gladwin, Mark, MD; Individual
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pre-Eclampsia, Hypertension in Pregnancy, Obesity
Interventions: Aspirin 81 mg, Aspirin 162 mg; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atherosclerosis
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 45 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypertension, Pulmonary
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diastolic Heart Failure, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Pulmonary Hypertension
Interventions: UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 56
States / cities: Phoenix, Arizona • Glendale, California • Irvine, California + 51 more

Conditions: Hypertension, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Comorbidities and Coexisting Conditions
Interventions: Improved Community Health Volunteer (CHV) program; Other
Lead sponsor: International Rescue Committee; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Heart Failure
Interventions: Remote Ischemic Conditioning (using Sphygmomanometer); Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Interventions: Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 4 Weeks to 18 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 8
States / cities: Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Formulation E1 of L-PPDS, Formulation E2 of L-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Mild Cognitive Impairment, Hypertension
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Obesity, Nutrition, Healthy
Interventions: Assigned Interventions; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Hyperlipidemia
Interventions: Free Generic Samples (hydrochlorothiazide, simvastatin); Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Cognitive Decline
Interventions: Tai Chi; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 55 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 17 Years to 90 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension
Interventions: fenofibrate, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension
Interventions: Trimethaphan, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost, Placebo Vehicle; Drug · Other
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 10
States / cities: Artesia, California • Colorado Springs, Colorado • Lakeland, Florida + 7 more

Conditions: Chronic Kidney Disease
Interventions: Self-management of BP medications, Self-monitoring of home BP; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease, Congestive Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, Sickle Cell Disease, Sleep Apnea, Smoking, Stroke, Tuberculosis
Interventions: Problem List Suggestion; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,386 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Portland, Oregon • Camp Hill, Pennsylvania + 1 more

Search by objective public record fields.

Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

Oral Nitrite Trial for Hypertension and Metabolic Syndrome

Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida

Aliskiren Effect on Aortic Plaque Progression

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Community Models for Hypertension and Diabetes Care for Refugees

The IMPULSE Study: Pilot

Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing

A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

Hypertension, Brain Clearance, and Markers of Neurodegeneration

Preparing FIM-BCS - A Lifestyle Modification for African-American Breast Cancer Survivors

The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

The Influence of Tai Chi Practice on Blood Pressure and Brain Health Among Older Adults With Hypertension (ACTION)

Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension

The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

Patient-driven Management of BP in CKD

Improving Quality by Maintaining Accurate Problems in the EHR